Regeneron Pharmaceuticals Inc (REGN) - Stock Report

The key macro issue is not biotechnology quality in isolation, but whether retina pricing and biosimilar pressure remain slow enough for Dupixent collaboration profit, EYLEA HD and owned launches to replace legacy cash after manufacturing costs, R&D, capex and repurchases.

The latest reported quarter is Q1 2026, not FY 2025: revenue rose 19% to $3.605 billion, reported diluted EPS was $6.75, and company-adjusted diluted EPS was $9.47, with both EPS figures absorbing acquired-IPR&D charges. The proof was mixed. Dupixent global net sales, recorded by Sanofi, rose 33% to $4.9 billion and Sanofi collaboration revenue rose 36% to $1.605 billion, but U.S. EYLEA HD sales of $468 million did not yet offset the legacy EYLEA decline, leaving combined U.S. EYLEA HD and EYLEA sales down 10% to $941 million. Cash after capex was about $848 million, while dividends plus repurchases were about $892 million, so the capital-return gap is a pacing signal rather than a full-year cash-coverage conclusion.

Regeneron is a founder-led biotechnology company that discovers, develops, manufactures and commercializes branded therapies for eye disease, immunology and inflammation, oncology, rare disease, cardiovascular and metabolic disorders, hematology, infectious disease and neurology. The economic stack is not a simple product list. EYLEA and EYLEA HD are the ophthalmology cash bridge, Dupixent is the external collaboration profit engine, Libtayo is the oncology growth contributor, and the VelociSuite discovery platform is the internal replacement system that reduces dependence on large-scale acquisitions.

The company reports as one consolidated business, but the per-share economics come from different roles. EYLEA 2 mg remains exposed to biosimilar and price pressure in the United States and outside the United States through Bayer. EYLEA HD is the defensive conversion product: it can preserve ophthalmology economics only if higher-dose dosing convenience offsets legacy-volume erosion and lower net price. Dupixent is different because Sanofi records global net sales and Regeneron receives collaboration economics; that makes Dupixent a high-value bridge, but not a fully owned revenue line.

Management is spending heavily to keep that bridge alive. Q1 2026 reported R&D was $1.544 billion and company-adjusted R&D was $1.408 billion, reflecting late-stage programs across hematology-oncology, complement-mediated disease, anticoagulation, obesity and rare disease. The business therefore earns its multiple only if current branded-cash durability funds a pipeline that becomes commercial cash flow before ophthalmology erosion absorbs the margin cushion.